Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366301 · ClinicalTrials.gov registry record · Phase 4
The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
NCT00366301 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 500 participants.
The verdict
NCT00366301, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study, which is being conducted at 100 centers throughout the United States, is to determine whether Lantus, a long-acting insulin injection, either alone or in combination with metformin, is effective in reducing C-reactive protein (CRP) in adults with type 2 diabetes. CRP is a marker of chronic low-level inflammation, a new risk factor for diabetes, heart attack, stroke, and other cardiovascular events.
Interventions
- DRUG Placebo pill
- DRUG metformin
- DRUG Insulin glargine injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366301
The ClinicalTrials.gov registry entry for NCT00366301 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo pill is the first listed.
NCT00366301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366301 about?
NCT00366301 is a clinical study titled "The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes". The purpose of this study, which is being conducted at 100 centers throughout the United States, is to determine whether Lantus, a long-acting insulin injection, either alone or in combination with metformin, is effective in reducing C-reactive protein (CRP) in adults with type 2 diabetes. CRP is a ...
What is the current status of trial NCT00366301?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2006-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00366301?
The interventions under investigation include: Placebo pill (DRUG), metformin (DRUG), Insulin glargine injection (DRUG).
Who is sponsoring clinical trial NCT00366301?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.